Grifols holds technical support, shares trade in a tight Nasdaq range
25.06.2026 - 18:56:11 | ad-hoc-news.de
By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-25, 18:55.
Grifols (ES0171996087) currently trades on Nasdaq via its ADR around 7 dollars after yesterday's close, with the shares fluctuating in a narrow band between support and resistance levels over recent sessions, according to TradingKey data.
What current charts show
On Nasdaq, Grifols American Depositary Receipts (ticker GRFS) closed at 7.22 dollars on 2026-06-24, a move of 0.56 percent for the day, according to MarketBeat price data.MarketBeat overview for Grifols TradingKey places short-term support at 6.81 dollars and resistance at 7.91 dollars, indicating that the stock is currently trading in the middle of this range.TradingKey technical analysis for GRFS
The same TradingKey analysis reports a price momentum score of 6.56 for Grifols, ranking the shares 112 out of 157 within the pharmaceuticals industry on this metric.TradingKey technical analysis for GRFS Based on moving averages from 5-day to 200-day periods, TradingKey counts zero buy signals and six sell signals, underlining a cautious technical picture in the short term.TradingKey moving average signals
Thursday focus on volatility and signals
The TradingKey overview notes that Grifols currently shows one technical buy signal versus four sell signals across indicators such as moving averages and oscillators, resulting in an overall daily signal categorized as "Sell" for traders following this methodology.TradingKey indicator summary for GRFS For range traders, the defined corridor between 6.81 and 7.91 dollars offers a concrete framework for potential swing strategies without implying any forecast.
MarketBeat data show a market capitalization for Grifols of roughly 6.23 billion dollars at a price of 7.22 dollars, underlining the company’s mid-cap status on Nasdaq within the medical and pharmaceutical segment.MarketBeat key figures for Grifols The same source lists Grifols in the pharmaceuticals products industry, positioning it alongside other global plasma and biotech players on US exchanges.
All news and analysis on the Grifols shares
Further company announcements, filings and market commentary on Grifols can be found in the dedicated topic section and on the official investor relations page.
The business behind the ticker
Grifols generates most of its revenue from plasma-derived therapies, with flagship products such as its intravenous immunoglobulin Gamunex-C and various albumin and coagulation factor concentrates used to treat immune deficiencies and bleeding disorders worldwide.Grifols biopharma product portfolio The group also operates a global network of plasma donation centers and provides diagnostic solutions for transfusion medicine laboratories.
Where the shares trade today
The Grifols ADRs (ES0171996087) last traded on Nasdaq at 7.22 dollars as of 2026-06-24, 16:00 Eastern Time, according to consolidated closing data.
Key data on the Grifols shares
- Company: Grifols, S.A.
- ISIN: ES0171996087
- WKN: A2ABGB
- Ticker: GRFS
- Trading venue: NASDAQ
- Price (as of 2026-06-24, 16:00): 7.22 USD
- Market cap: 6.23 billion USD (as of 2026-06-24)
- Sector / industry: Health care / Biopharmaceuticals
- Index membership: not a member of S&P 500 or NASDAQ-100
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any financial instrument, or any form of personalized financial guidance.
